ÂÜÀòÂÒÂ×

Andrew Young is a Scientific & Clinical Advisor at Glyscend Incorporated. Andrew was previously the VP and Head of Enteroendocrine Biology at GlaxoSmithKline from December 2008 to March 2015. Prior to that, they were the CMO at Leptos Biomedical from January 2007 to December 2008, where they oversaw preclinical and clinical programs of an active antiobesity device.

From January 1989 to December 2008, Andrew Young was the VP Sr Research Fellow at Amylin Pharmaceuticals, where they coauthored a peptide hormone discovery initiative, finding novel ligands, and in vivo screening for novel utilities of those and known peptide ligands.

Before that, from March 1987 to October 1989, they were a Lecturer in Physiology at The University of Auckland, where they were responsible for teaching systems physiology and laboratory courses for 2nd year medical and science students.

Andrew has also been the Chief Scientific Officer and Co-founder at Phoundry Pharmaceuticals Inc from March 2015 to September 2015, and the Founder at Satiogen from January 2007 to December 2009. Additionally, they have been on the scientific advisory board (SAB) of GI Dynamics from January 2003 to December 2007.